Asia Executives To Watch: Novartis China, GSK India, Cipla
Novartis’s former head of West China is moving to lead its global cardio-metabolic franchise, while GSK India and Cipla have made key personnel appointments on the manufacturing front.
You may also be interested in...
Indian firms have been making extensive efforts to improve their compliance record, including getting on board top-notch global talent. Cipla, which recently appointed a new head of respiratory manufacturing, has tapped an ex-FDA investigator as its audit and compliance director.
India’s new draft pharmaceutical policy proposes a raft of radical changes that have left industry jittery and could force a significant realignment in the operations of foreign and local firms. Second brand strategies and widespread licensing-out of manufacturing are no longer favored, and a 'one company – one drug – one brand name – one price' thrust are among the key changes proposed.
Cipla's US business appears set to gain momentum with a string of differentiated generic launches lined up and the firm's CEO shares key insights into how price peaks and troughs could potentially play out in the world's largest pharmaceutical market.